| IT |
Report |
Adjusted EPS |
BEAT |
pred ~$3.84 vs. cons $3.76 |
MEDIUM |
| IT |
Report |
Adjusted EBITDA excluding divested operation |
BEAT |
pred ~$445M vs. cons $438M |
MEDIUM |
| IT |
Report |
Total contract-value growth (FX-neutral) |
MISS |
pred ~2.6% vs. cons 3.5% |
MEDIUM |
| IT |
Guide |
FY2026 adjusted revenue guidance |
LOWER |
guide ~$6.405B vs. cons $6.43B (FY2026) |
MEDIUM |
| IT |
Guide |
FY2026 adjusted EBITDA guidance |
UNCHANGED |
guide ~$1.545B vs. cons $1.55B (FY2026) |
MEDIUM |
| IT |
Guide |
FY2026 adjusted EPS guidance |
LOWER |
guide ~$13.25 vs. cons $13.48 (FY2026) |
MEDIUM |
| IT |
Guide |
FY2026 free-cash-flow guidance |
LOWER |
guide ~$1.16B vs. cons $1.18B (FY2026) |
MEDIUM |
| IT |
Guide |
Exit-rate total contract-value growth commentary |
LOWER |
guide ~4.0% vs. cons 5.0% (Q4 2026 exit rate) |
LOW |
| IT |
Return |
Day-1 residual (stock − beta × S&P 500) |
-7.5% |
— |
MEDIUM |
| IT |
Return |
5-day cumulative residual |
-10.5% (FOLLOW-THROUGH) |
A modest EPS/EBITDA beat is likely to be discounted if total CV grows only ~2.6% versus ~3.5% expected and management effectively maintains FY profit and cash-flow targets below current estimates. The weaker CV conversion and less-convincing exit-rate commentary imply 2027 revenue and EPS estimate cuts, creating negative revisions after the initial reaction. |
MEDIUM |